Long-term safety and efficacy of lasmiditan for acute treatment of migraine: Final results of the GLADIATOR study
GLADIATOR was a prospective, randomized, open-label, phase 3 study of lasmiditan 100 mg or 200 mg dosed intermittently for up to 1 year in patients with episodic migraine. Most patients had completed one of two single-attack studies before participation. A total of 2030 patients received ≥1 lasmidit...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2020-09-01
|
| Series: | Cephalalgia Reports |
| Online Access: | https://doi.org/10.1177/2515816320958176 |